Fragment Hits: What do They Look Like and How do They Bind?

A “fragment hit”, a molecule of low molecular weight that has been validated to bind to a target protein, can be an effective chemical starting point for a drug discovery project. Our ability to find and progress fragment hits could potentially be improved by enhancing our understanding of their binding properties, which to date has largely been based on tacit knowledge and reports from individual projects. In the work reported here, we systematically analyzed the molecular and binding properties of fragment hits using 489 published protein–fragment complexes. We identified a number of notable features that these hits tend to have in common, including preferences in buried surface area upon binding, hydrogen bonding and other directional interactions with the protein targets, structural topology, functional-group occurrence, and degree of carbon saturation. In the future, taking account of these preferences in designing and selecting fragments to screen against protein targets may increase the chances of success in fragment screening campaigns.

[1]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[2]  Johannes Schiebel,et al.  Six Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study. , 2016, ACS chemical biology.

[3]  T. Blundell,et al.  Fragment-based drug discovery in academia: Experiences from a tuberculosis programme , 2009 .

[4]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[5]  G. McGaughey,et al.  Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. , 2015, Journal of medicinal chemistry.

[6]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[7]  Tjelvar S. G. Olsson,et al.  Identifying Interactions that Determine Fragment Binding at Protein Hotspots. , 2016, Journal of medicinal chemistry.

[8]  G. Keserű,et al.  On the enthalpic preference of fragment binding , 2016 .

[9]  Christopher W Murray,et al.  Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.

[10]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.

[11]  Tjelvar S. G. Olsson,et al.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.

[12]  G. Klebe,et al.  Experimental Active-Site Mapping by Fragments: Hot Spots Remote from the Catalytic Center of Endothiapepsin. , 2016, Journal of medicinal chemistry.

[13]  M. Nishio,et al.  The CH/π hydrogen bond in chemistry. Conformation, supramolecules, optical resolution and interactions involving carbohydrates. , 2011, Physical chemistry chemical physics : PCCP.

[14]  W. Patrick Walters,et al.  Prediction of Protein Pairs Sharing Common Active Ligands Using Protein Sequence, Structure, and Ligand Similarity , 2016, J. Chem. Inf. Model..

[15]  B. Davis,et al.  Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. , 2012, Bioorganic & medicinal chemistry.

[16]  Paul N. Mortenson,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2017. , 2018, Journal of medicinal chemistry.

[17]  G. Keserű,et al.  Fragment-based lead discovery on G-protein-coupled receptors , 2013, Expert opinion on drug discovery.

[18]  Marcel L Verdonk,et al.  Detection of secondary binding sites in proteins using fragment screening , 2015, Proceedings of the National Academy of Sciences.

[19]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[20]  R. Trievel,et al.  Carbon-Oxygen Hydrogen Bonding in Biological Structure and Function , 2012, The Journal of Biological Chemistry.

[21]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[22]  Dima Kozakov,et al.  Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. , 2015, Trends in pharmacological sciences.

[23]  Tao Lu,et al.  Intermolecular Sulfur···Oxygen Interactions: Theoretical and Statistical Investigations , 2015, J. Chem. Inf. Model..

[24]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[25]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[26]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[27]  Rajarshi Guha,et al.  KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries , 2011, Molecular informatics.

[28]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[29]  P. Labute proteins STRUCTURE O FUNCTION O BIOINFORMATICS Protonate3D: Assignment of ionization , 2013 .

[30]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[31]  Gerhard Klebe,et al.  Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why. , 2015, Journal of medicinal chemistry.

[32]  J. Hert,et al.  Interactive and Versatile Navigation of Structural Databases. , 2016, Journal of medicinal chemistry.

[33]  Paul N. Mortenson,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2018. , 2020, Journal of medicinal chemistry.

[34]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[35]  V. Nienaber,et al.  Identification and optimization of PDE 10 A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography , 2014 .

[36]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[37]  Daniel A Erlanson,et al.  Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.

[38]  G. Klebe Applying thermodynamic profiling in lead finding and optimization , 2015, Nature Reviews Drug Discovery.

[39]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[40]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[41]  Paul N. Mortenson,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2016. , 2017, Journal of medicinal chemistry.

[42]  Pierangelo Metrangolo,et al.  The Halogen Bond , 2016, Chemical reviews.

[43]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[44]  Gianni Chessari,et al.  Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.

[45]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J Willem M Nissink,et al.  Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. , 2015, Journal of medicinal chemistry.

[47]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[48]  Vincent Le Guilloux,et al.  Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.

[49]  Thomas A. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[50]  Bernhard Rupp,et al.  Models of protein–ligand crystal structures: trust, but verify , 2015, Journal of Computer-Aided Molecular Design.

[51]  V. Nienaber,et al.  Identification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray Crystallography , 2014, Journal of biomolecular screening.

[52]  Iina Hellsten,et al.  When fragments link: a bibliometric perspective on the development of fragment-based drug discovery. , 2018, Drug discovery today.

[53]  O. Carugo,et al.  How many water molecules can be detected by protein crystallography? , 1999, Acta crystallographica. Section D, Biological crystallography.

[54]  Edward R Zartler,et al.  Fragonomics: the -omics with real impact. , 2014, ACS medicinal chemistry letters.

[55]  Martin Stahl,et al.  Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis , 2008, J. Chem. Inf. Model..

[56]  A. Petrauskas,et al.  ACD/Log P method description , 2000 .

[57]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[58]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[59]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[60]  T. Blundell,et al.  Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.

[61]  György G. Ferenczy,et al.  Thermodynamics of Fragment Binding , 2012, J. Chem. Inf. Model..

[62]  J. Reymond The chemical space project. , 2015, Accounts of chemical research.

[63]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[64]  C. Murray,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2015. , 2017, Journal of medicinal chemistry.